FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Receives Key Diabetes Drug Approval

Key Takeaways

• FDA grants approval for LANGLARA as an interchangeable biosimilar to Lantus insulin glargine for diabetes treatment
• Approval covers both adult and pediatric patients, expanding treatment access and potentially reducing costs
• Lannett Company, through subsidiary Lanexa Biologics and partner Sunshine Lake Pharma, can now market the biosimilar insulin

---

PHILADELPHIA - Lannett Company, Inc., along with its wholly owned subsidiary Lanexa Biologics and partner Sunshine Lake Pharma, announced today that the U.S. Food and Drug Administration (FDA) has approved LANGLARA™ (insulin glargine-aldy) as an interchangeable biosimilar to Lantus® (insulin glargine) for treating diabetes in both adults and pediatric patients.

Market Impact and Patient Access

The approval represents a significant milestone in diabetes care, as interchangeable biosimilars can be substituted for reference products at the pharmacy level without prescriber intervention. This designation could improve patient access to long-acting insulin therapy while potentially reducing healthcare costs.

Lantus, manufactured by Sanofi, has been a cornerstone treatment for Type 1 and Type 2 diabetes patients requiring long-acting insulin. The introduction of LANGLARA provides healthcare providers and patients with an FDA-approved alternative that meets the same safety and efficacy standards.

Regulatory Significance

The FDA’s interchangeable designation is particularly noteworthy, as it requires extensive clinical data demonstrating that patients can switch between the biosimilar and reference product multiple times without compromising safety or efficacy. This rigorous standard ensures patient confidence in biosimilar treatments.

Company Collaboration

The approval reflects successful collaboration between Lannett Company and Sunshine Lake Pharma in developing complex biosimilar products. Lanexa Biologics, established as Lannett’s biosimilar-focused subsidiary, spearheaded the regulatory pathway for this insulin product.

Industry Context

This approval adds to the growing biosimilar insulin market in the United States, where diabetes affects over 37 million Americans. Increased competition in the insulin space has been a priority for regulators and healthcare advocates seeking to address medication affordability concerns.

The companies have not yet announced specific launch timelines or pricing information for LANGLARA, though interchangeable biosimilars typically offer cost savings compared to reference products.

---

Frequently Asked Questions

What does interchangeable biosimilar status mean for patients?

Interchangeable status means pharmacists can substitute LANGLARA for Lantus without requiring a new prescription from the doctor, similar to how generic drugs work, potentially improving access and reducing costs.

When will LANGLARA be available in pharmacies?

The companies have not announced a specific launch date. Availability will depend on manufacturing scale-up, distribution agreements, and insurance coverage negotiations following FDA approval.

How does LANGLARA compare to Lantus in terms of effectiveness?

As an FDA-approved interchangeable biosimilar, LANGLARA has demonstrated equivalent safety and efficacy to Lantus through extensive clinical trials, with no clinically meaningful differences in treatment outcomes.